Stocktwits55d agoneutral
IBRX Stock Gains As Soon-Shiong’s Nant Capital Backs Second Cancer-Immunotherapy BetNews
High-signal headlines only - macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.
106last 24h
3125last 7d
511● bullish (7d)
311● bearish (7d)
227publishers
Stocktwits83d agoneutral
Goldman Sachs Builds $75M Bet Across CAPR, SLS And IBRX As Major Catalysts LoomSimply Wall St.93d agoneutral
The Bull Case For ImmunityBio (IBRX) Could Change Following ANKTIVA’s Broad UAE Approval And Ongoing LossesInvestorsHub101d agoneutral
ImmunityBio Gains After UAE Approves ANKTIVA for Bladder and Lung Cancer Treatments24/7 Wall St.121d agobearish
Moderna Drops 11%, ImmunityBio and Sarepta Therapeutics Tumble 8% in Biotech RoutStocktwits121d agobullish
Can IBRX Stock Keep Its Pulse? Institutional Investors Buy In, Retail Hopes For Big Q2 Surprise